Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for p… Read more
Knight Therapeutics Inc (KHTRF) - Total Liabilities
Latest total liabilities as of September 2025: $282.18 Million USD
Based on the latest financial reports, Knight Therapeutics Inc (KHTRF) has total liabilities worth $282.18 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Knight Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Knight Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Knight Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Knight Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou W Deane New Power Elec
SHG:603312
|
China | CN¥1.20 Billion |
|
Miracll Chemicals Co Ltd
SHE:300848
|
China | CN¥2.74 Billion |
|
Transport International Holdings Limited
F:KWO
|
Germany | €7.04 Billion |
|
Zhejiang Baida Precision Mnfg
SHG:603331
|
China | CN¥1.97 Billion |
|
Shandong Longji Machinery Co Ltd
SHE:002363
|
China | CN¥936.23 Million |
|
Henan Carve Electronics Technology Co. Ltd.
SHE:301182
|
China | CN¥1.02 Billion |
|
Bosung Power Technology Co. Ltd
KQ:006910
|
Korea | ₩29.96 Billion |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
China | CN¥2.19 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Knight Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Knight Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Knight Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Knight Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $168.69 Million | -15.07% |
| 2023-12-31 | $198.62 Million | -13.26% |
| 2022-12-31 | $228.98 Million | +52.78% |
| 2021-12-31 | $149.87 Million | -2.32% |
| 2020-12-31 | $153.44 Million | -60.68% |
| 2019-12-31 | $390.20 Million | +1689.89% |
| 2018-12-31 | $21.80 Million | +47.55% |
| 2017-12-31 | $14.78 Million | +33.69% |
| 2016-12-31 | $11.05 Million | +59.57% |
| 2015-12-31 | $6.93 Million | -9.14% |
| 2014-12-31 | $7.62 Million | -- |